Stopping Lymphedema Starts with PREVENT - Final 3-Year Primary Endpoint Results Published

The Global Leader in BIS Technology

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.

Learn More About BIS
Investor Relations

Share Purchase Plan (SPP) Offer

About the SPP

The SPP aims to raise up to approximately $5 million and is not underwritten. ImpediMed may decide to accept applications (in whole or part) that result in the SPP raising more or less than this amount, in its absolute discretion. Should any scale back be necessary, it is ImpediMed’s intention that any scale back arrangements will be made having regard to the pro rata shareholdings of Eligible Shareholders who apply for SPP Shares. The SPP follows ImpediMed’s placement to sophisticated and institutional investors, which raised approximately $20 million (Placement).

The SPP Shares are being offered at an Issue Price of $0.13.

How to Participate in the Offer

The SPP opens on Tuesday, 30 May 2023 and is expected to close at 5:00pm (AEST) on Friday, 16 June 2023.

To apply for SPP Shares, you must by 5:00pm (AEST) on Friday, 16 June 2023, either:

  • download the Booklet and your personalised Application Form and make a payment directly via BPAY® (all Eligible Shareholders); or
  • download the Booklet and your personalised Application Form and make a payment directly via Electronic Funds Transfer (EFT) (New Zealand Eligible Shareholders only).

Please refer to the Offer Site for additional details and to complete the required forms:


A copy of the booklet can be downloaded here:


Ensure your payment is received by the Share Registry before 5.00pm on Friday 16 June 2023.

For further information on the SPP you can call the Registry, between 8.30am and 5.00pm (AEST) Monday to Friday on +61 1800 677 648.

Growth Through SOZO SaaS Subscription-Based Model

ImpediMed produces a family of FDA-cleared and CE-marked medical devices, including SOZO® for multiple indications, including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally. ImpediMed’s connected digital health platform and large, attractive and growing markets present an opportunity for continued strong growth through its SOZO SaaS subscription-based business.

Growth Through SOZO SaaS Subscription-based Model

SOZO Business Performance

Q3 FY’23


YOY in the Core Business


YOY in the Core Business


YOY^ in the Core Business


with 30%+ increase
In Average Monthly License Fees^^


Across the Business


Across all SOZO Systems

All FY’23 revenue and cash flow numbers are unaudited.
All figures are stated in Australian dollars (AUD) unless otherwise notated.
All percentages are stated based on change in Constant Currency (CC).
^ YOY denotes Year-over-Year change in metric.
^^ Based on US SOZO Contracts renewed during the time period.
i Annual Recurring Revenue (ARR): The amount of revenue reasonably expected to be booked for the next 12-month period based on existing signed contracts, and assuming installation upon sale.
ii Total Contract Value (TCV): Total value of customer contracts including one-time and recurring revenue.
iii Contracted Revenue Pipeline (CRP): Future period revenue amounts related to TCV that are yet to be reported as recognised revenue.
CRP, ARR and TCV are non-IFRS financial metrics that do not represent revenue in accordance with Australian Accounting Standards.

Market Performance

4C Q3 FY'23

Quarterly Results Conference Call

4C Q3 FY'23

Quarterly Results Investor Presentation

MAY 2023

Complete Investor Presentation

Analyst coverage

ImpediMed has market-leading coverage with the following entities:

Share register

ImpediMed Limited is listed on the Australian Stock Exchange (ASX). Trading in its securities is under the ticker code on ASX of “IPD” for ordinary shares.

Share register agent

To update shareholder contact information or submit transfer documents, please contact ImpediMed’s share register service provider:

Ph: +1300-554-474
Fax: +61-2-9287-0303

Locked Bag A14
Sydney South
NSW 1235, Australia

Shareholder services

Shares may be bought on market through any Australian stock broker, or through on-market trades, via a number of international brokerage houses. If you are a potential investor needing information on how to trade in shares through an international brokerage house, please contact:

ImpediMed maintains an active communications program with investors and the market.

My shareholding

ImpediMed’s share register is managed by Link Market Services Limited.

ImpediMed is focused on reducing our carbon footprint whilst providing you with timely corporate updates and disclosures.

Recent legislative changes to the Corporations Act 2001 (Cth) mean there are new options for how ImpediMed shareholders receive communications. ImpediMed will no longer send physical meeting documents unless a shareholder requests a copy to be mailed.

Electronic communication has the added advantage of being timelier and more cost effective, which benefits all shareholders, and ImpediMed encourages all shareholders to provide an email address so we can communicate with you electronically when shareholder notices become available online, for items such as meeting documents, dividend statements and annual reports.

Shareholders can still elect to receive some or all of their communications in physical or electronic form. To review your communication preference, or sign up to receive your shareholder communications via email, please update your details at the Link Investor Centre

If you are a Shareholder and require an additional copy of a communication, need further information about the options available to you or have questions about your holding, visit the Link Investor Centre or contact the Registry:

Link Market Services
Locked Bag A14
Sydney South NSW 1235
P: +61 1300 554 474 (toll free within Australia)

Shareholders can use the Link Investor Centre at to:

Set up and add their holdings to a portfolio
Review and update their contact details, communication preferences and payment
Provide their TFN and/or ABN
View their holding details
Make online enquiries

To view your shareholding Link Investor Centre, visit:

Investor Relations Contact

Hannah Howlett
WE Communications
+61 (0) 4 5064 8064